Premium
P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study
Author(s) -
Cummings Jeffrey,
Bellelli Giuseppe,
Black Sandra,
Bakchine Serge,
Krahnke Tillmann,
Strohmaier Christine
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1352
Subject(s) - rivastigmine , tolerability , transdermal patch , medicine , adverse effect , activities of daily living , randomized controlled trial , clinical endpoint , transdermal , randomization , anesthesia , dementia , disease , pharmacology , physical therapy , donepezil